罗氟司特治疗慢性阻塞性肺疾病的研究进展

被引:3
作者
魏佳
程德云
机构
[1] 四川大学华西医院呼吸内科
关键词
慢性阻塞性肺疾病; 急性加重; 磷酸二酯酶-4抑制剂; 罗氟司特;
D O I
暂无
中图分类号
R563.9 [其他];
学科分类号
100201 [内科学];
摘要
目的:为临床合理使用罗氟司特治疗慢性阻塞性肺疾病(COPD)提供参考。方法:查阅近年来国内外相关文献,对罗氟司特治疗COPD的药效学、药动学、药物相互作用、临床有效性和安全性等方面的进展进行归纳和总结。结果:罗氟司特具有强大的抗炎作用和中等程度的支气管扩张作用,可以有效改善肺功能,显著降低中/重度COPD患者的平均恶化率,预防急性加重;其活性代谢产物N-氧化物(RNO)在体内可以逆转糖皮质激素依赖,单用或与糖皮质激素联用均能发挥强大的抗炎效应,且不增加COPD患者严重不良心血管事件的发生率。结论:在充分评估患者严重程度和急性加重风险的基础上,罗氟司特联合支气管扩张剂治疗能使患者获益,但尚需进一步开展国际性、大规模、多中心综合临床研究。
引用
收藏
页码:4168 / 4171
页数:4
相关论文
共 6 条
[1]
Roflumilast N-oxide reverses corticosteroid resistance in neutrophils from patients with chronic obstructive pulmonary disease [J].
Milara, Javier ;
Lluch, Javier ;
Almudever, Patricia ;
Freire, Jose ;
Qian Xiaozhong ;
Cortijo, Julio .
JOURNAL OF ALLERGY AND CLINICAL IMMUNOLOGY, 2014, 134 (02) :314-+
[2]
Roflumilast: the new orally active, selective phophodiesterase-4 inhibitor, for the treatment of COPD [J].
Tashkin, Donald P. .
EXPERT OPINION ON PHARMACOTHERAPY, 2014, 15 (01) :85-96
[3]
Efficacy and safety of roflumilast in patients with stable chronic obstructive pulmonary disease: A meta-analysis.[J].Jun-Hong Yan;Wan-Jie Gu;Lei Pan.Pulmonary Pharmacology & Therapeutics.2013,
[4]
Roflumilast N-oxide, a PDE4 inhibitor, improves cilia motility and ciliated human bronchial epithelial cells compromised by cigarette smoke in vitro [J].
Milara, J. ;
Armengot, M. ;
Banuls, P. ;
Tenor, H. ;
Beume, Rolf ;
Artigues, E. ;
Cortijo, J. .
BRITISH JOURNAL OF PHARMACOLOGY, 2012, 166 (08) :2243-2262
[5]
Roflumilast attenuates pulmonary inflammation upon segmental endotoxin challenge in healthy subjects: A randomized placebo-controlled trial [J].
Hohlfeld, Jens M. ;
Schoenfeld, Kerstin ;
Lavae-Mokhtari, Mehyar ;
Schaumann, Frank ;
Mueller, Meike ;
Bredenbroeker, Dirk ;
Krug, Norbert ;
Hermann, Robert .
PULMONARY PHARMACOLOGY & THERAPEUTICS, 2008, 21 (04) :616-623
[6]
Pathophysiology of airflow limitation in chronic obstructive pulmonary disease [J].
Hogg, JC .
LANCET, 2004, 364 (9435) :709-721